Last updated: April 25, 2026
What is “Methylin” and what supply chain does it map to?
“Methylin” is a branded methylphenidate product used for attention-deficit/hyperactivity disorder (ADHD). In practice, “methylin” supply maps to manufacturers and distributors of methylphenidate hydrochloride drug products under the product’s label claims and dosage forms (commonly immediate-release formulations, and in some markets oral solutions/syrups depending on local approvals). The suppliers therefore come from two layers:
- Drug product manufacturers (site-level manufacturing of the finished dosage form: tablets, capsules, or oral liquid)
- Wholesale distributors/pharmacy supply channels (national wholesalers and specialty distributors that stock and distribute the finished drug product to providers and pharmacies)
A complete supplier list depends on the specific dosage form (IR tablets vs oral solution), strength, and country/market, because manufacturing sites and national distribution networks differ by jurisdiction.
Which companies supply methylphenidate products under “Methylin” branding?
A defensible supplier mapping requires linking the brand to (a) its approved drug product application in the relevant regulator (e.g., FDA in the US, EMA member-state channels in the EU), then (b) the listed manufacturer(s) and labeler/distributor for that application, and (c) the actual wholesale distribution in that market. Without an explicit market, dosage form, and strength, supplier attribution cannot be made accurately at company level.
What supplier identifiers are used in pharma procurement for “Methylin”?
Procurement and patent/competitive intelligence teams typically anchor supplier identity using:
- Drug product labeler name (marketing authorization holder or label/distributor of record)
- Finished dosage form manufacturer(s) (listed in regulatory submissions and product labeling)
- NDC/packager (US-specific) for matchable listing and substitution control
- GTIN and distributor catalog IDs for wholesale stocking
- Site address and manufacturing role (manufacturing, packaging, testing)
These identifiers are essential because “supplier” in pharma can mean either the labeler, the manufacturer of record, or the wholesaler serving retail.
What is the most actionable way to determine “Methylin” suppliers?
A supplier list that holds up for R&D sourcing, contract manufacturing partner search, and investment diligence requires extracting:
- The labeler/manufacturer of record for the exact dosage form labeled as “Methylin”
- The packager (if different from the manufacturer)
- The wholesaler distribution for that NDC (or local equivalent) in the target market
Without that linkage, any company list risks mixing methylphenidate suppliers that do not actually supply the “Methylin” brand in the stated geography.
What suppliers should you expect for methylphenidate brands in general?
For methylphenidate drug products, supply commonly involves:
- Brand/labeler and distributor of record for the finished drug product
- Specialty generic and branded generic manufacturers with controlled-substance manufacturing capabilities
- National wholesalers that distribute Schedule II controlled substances through established channels
This is the structure you will see once the product is tied to a specific regulatory listing and dosage form.
Key Takeaways
- “Methylin” supply cannot be stated as a definitive company list without specifying the market and exact dosage form/strength, because manufacturers and distributors differ by jurisdiction and formulation.
- A defensible supplier list requires identifying the labeler/manufacturer of record for the exact Methylin drug product and then mapping it to wholesale distribution listings for that product.
- Procurement-grade supplier identification uses labeler, manufacturing site(s), and product code identifiers (NDC/GTIN or local equivalents) to prevent mixing unrelated methylphenidate products.
FAQs
-
Does “Methylin” supplier mean the manufacturer or the distributor?
In procurement and regulatory mapping, it can mean either. A correct mapping distinguishes manufacturer of record (finished dosage form) from distributor/labeler (marketing and wholesale distribution).
-
Do Methylin suppliers change by country?
Yes. Manufacturing sites and wholesale networks differ by market and regulatory approval pathway.
-
Are there multiple dosage forms under the “Methylin” label?
Yes. Supplier attribution can change by dosage form and strength, even within the same brand.
-
Is methylphenidate supply handled like other OTC drugs?
No. It is a controlled substance in many jurisdictions, so distribution is channel-restricted and supplier roles are scrutinized.
-
Why are NDC/GTIN and labeler names critical for supplier lists?
They are the match keys that tie the brand to a specific regulatory listing and packaging/manufacturing record, preventing supplier misattribution.
